• Dépistage, diagnostic, pronostic

  • Découverte de technologies et de biomarqueurs

  • Colon-rectum

Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profiling

Menée à partir du séquençage de l'ADN de différentes régions d'échantillons tumoraux prélevés sur 12 patients atteints d'un cancer colorectal et menée à l'aide de 175 échantillons plasmatiques, cette étude analyse l'hétérogénéité mutationnelle des tumeurs et met en évidence la possibilité de développer, à partir d'une seule biopsie, des sondes PCR personnalisées pour le suivi postopératoire de l'évolution de la maladie à l'aide de l'ADN tumoral circulant

Background : Circulating tumour DNA (ctDNA) is known as a tumour-specific personalised biomarker, but the mutation-selection criteria from heterogeneous tumours remain a challenge.

Methods : We conducted multiregional sequencing of 42 specimens from 14 colorectal tumours of 12 patients, including two double-cancer cases, to identify mutational heterogeneity to develop personalised ctDNA assays using 175 plasma samples.

Results : “Founder” mutations, defined as a mutation that is present in all regions of the tumour in a binary manner (i.e., present or absent), were identified in 12/14 tumours. In contrast, “truncal” mutations, which are the first mutation that occurs prior to the divergence of branches in the phylogenetic tree using variant allele frequency (VAF) as continuous variables, were identified in 12/14 tumours. Two tumours without founder and truncal mutations were hypermutators. Most founder and truncal mutations exhibited higher VAFs than “non-founder” and “branch” mutations, resulting in a high chance to be detected in ctDNA. In post-operative long-term observation for 10/12 patients, early relapse prediction, treatment efficacy and non-relapse corroboration were achievable from frequent ctDNA monitoring.

Conclusions : A single biopsy is sufficient to develop custom dPCR probes for monitoring tumour burden in most CRC patients. However, it may not be effective for those with hypermutated tumours.

British Journal of Cancer , article en libre accès, 2021

Voir le bulletin